Inhibition of CRLF1 expression by miR-8485 alleviates IL-1β-induced chondrocyte inflammation, apoptosis, and extracellular matrix degradation
International Immunopharmacology · 2025-01 · 144 · 113643
DOI: 10.1016/j.intimp.2024.113643 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025-01. Verfasst von Guang Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China; National Clinical Research Center for Geriatric…. Hauptthemen laut MEDLINE: Chondrocytes, MicroRNAs, Interleukin-1beta, Osteoarthritis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science and Technology Program of Hunan Province, Wu Jieping Medical Foundation, Administration of Traditional Chinese Medicine of Jilin Province.
Abstract (Originalsprache)
The aim of this study was to investigate the impact of differentially expressed miR-8485 on chondrocyte inflammation in osteoarthritis (OA) and its underlying pathological mechanisms. MiR-8485, which was downregulated in OA, was identified by microarray analysis, and was also found to be decreased in IL-1β-induced C28/I2 cells. miR-8485 down-regulation or IL-1β treated of C28/I2 cells induces a decrease in cellular activity, an increase in apoptosis, an elevation in Cleaved caspase-3, MMP13, and ADAMTS5 protein levels, a decrease in Collagen II and Aggrecan levels, and an increase in the levels of pro-inflammatory factors TNF-α and IL-6. CRLF1 was identified to be a downstream target gene of miR-8485 using bioinformatics prediction and dual luciferase reporter gene assays. CRLF1 was shown to be increased in IL-1β-treated C28/I2 cells, and CRLF1 overexpression partially abrogated the suppressive effect of upregulated miR-8485 on chondrocyte inflammation. In addition, miR-8485 was able to inhibit MAPK/ERK and PI3K/AKT signaling activation by inhibiting CRLF1. In conclusion, miR-8485 was able to inhibit CRLF1 expression and thus inhibit IL-1β-triggered inflammation in chondrocytes, potentially through the inhibition of MAPK/ERK and PI3K/AKT signaling pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedics, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China; National Clinical Research Center for Geriatric Disorders, Department of Geriatrics, Xiangya Hospital, Central South…
- Department of Joint Surgery, Honghui Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi, China. Electronic address: Orth_shuguang@163.com.
Förderung
- Science and Technology Program of Hunan Province
- Wu Jieping Medical Foundation
- Administration of Traditional Chinese Medicine of Jilin Province
- National Natural Science Foundation of China
- Xiangya Hospital, Central South University
- National Key Research and Development Program of China
- Hunan Provincial Innovation Foundation for Postgraduate
Zitieren
APA
Yang, G., Ji, B., Li, H., Liu, X., Liu, G., Sun, J., Yao, Y., Li, Y., Liu, S., & Xiao, W. (2025). Inhibition of CRLF1 expression by miR-8485 alleviates IL-1β-induced chondrocyte inflammation, apoptosis, and extracellular matrix degradation. International Immunopharmacology, 144, 113643. https://doi.org/10.1016/j.intimp.2024.113643
Vancouver
Yang G, Ji B, Li H, Liu X, Liu G, Sun J, et al. Inhibition of CRLF1 expression by miR-8485 alleviates IL-1β-induced chondrocyte inflammation, apoptosis, and extracellular matrix degradation. International Immunopharmacology. 2025;144:113643. doi:10.1016/j.intimp.2024.113643
BibTeX
@article{Yang2025,
author = {Yang, Guang and Ji, Bingzhou and Li, Hengzhen and Liu, Xiu and Liu, Gaoming and Sun, Jianfeng and Yao, Yuming and Li, Yusheng and Liu, Shuguang and Xiao, Wenfeng},
title = {Inhibition of CRLF1 expression by miR-8485 alleviates IL-1β-induced chondrocyte inflammation, apoptosis, and extracellular matrix degradation},
journal = {International Immunopharmacology},
year = {2025},
volume = {144},
pages = {113643},
doi = {10.1016/j.intimp.2024.113643}
}
EUVIMED